Now approved in EU
The European Commission has granted a Marketing Authorization for Defitelio® (defibrotide) for the treatment of severe hepatic veno-occlusive disease (sVOD) in adults and children undergoing hematopoietic stem cell transplantation therapy.
Defibrotide is marketed in E.U. as Defitelio® - Learn more
More General News
More Financial News
In case of any side effects following the use of our drugs, please contact us
In caso di effetto/i indesiderato/i successivamente all’utilizzo di uno dei nostri farmaci, contattaci
For any medical information enquiries please contact:
Tel: +39 031 5373 112
Gentium S.p.A. is a
Jazz Pharmaceuticals company.
To learn more about Jazz Pharmaceuticals, click here
Gentium S.p.A. - P.IVA n. 02098100130
Most computers will open PDF documents automatically, but you may need to download Adobe Reader.